Research programme: anti-latent virus therapy - Gemin X

Drug Profile

Research programme: anti-latent virus therapy - Gemin X

Alternative Names: Anti-latent virus therapy research programme - Gemin X

Latest Information Update: 27 May 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gemin X Biotechnologies
  • Class Oncolytic viruses
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Epstein-Barr virus infections; Herpesvirus infections

Most Recent Events

  • 22 Mar 2004 This programme is still in active development
  • 18 Oct 2001 Preclinical development for Epstein-Barr virus infections in Canada (Unknown route)
  • 18 Oct 2001 Preclinical development for Herpesvirus infections in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top